- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02098187
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers (ORFM-1B)
Pilot 1B Study-Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 22 years of age or older
- Sex: Males and not of childbearing potential females
- Capable of informed consent
Weight restrictions:
- at least 50 kg (110 lbs) for men
- at least 48 kg (106 lbs) for women
- all participants will have a Body Mass Index (BMI) less than or equal to 33 but greater than or equal to 19
- All participants should be judged by the Principal Investigator or Medical Sub-Investigator physician as normal and healthy during a pre-study medical evaluation performed within 28 days of the initial dose of study medication
Exclusion Criteria:
- Institutionalized participants will not be used
- History of any significant cardiovascular disease, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic (including any history of seizure disorder), psychological, musculoskeletal disease or malignancies unless deemed not clinically significant by the Principal Investigator or Medical Sub-Investigator.
- Donation or loss of blood or plasma: 50 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication.
- Intolerance to venipuncture.
- Participants who have received an investigational drug within 30 days prior to the initial dose of study medication.
- History of drug and/or alcohol abuse within the past year, unless currently enrolled in an abstinence program.
- History of allergy or hypersensitivity to MP-3180 or iohexol, or other related products, or any of the inactive ingredients.
- History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape).
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Medical Sub-Investigator, could contraindicate the participant's participation in this study.
- History of allergy or hypersensitivity to iodine containing contrast media or drugs.
- Acute illness at the time of either the pre-study medical evaluation or dosing.
Social Habits:
- Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
- Ingestion of any vitamins or herbal supplement within 7 days prior to the initial dose of study medication.
- Any significant change in dietary or exercise habits within the 48 hours prior to the initial dose of study medication.
Medications:
a. Use of any prescription or over-the-counter (OTC) medications within the 7 days prior to the initial dose of study medication.
- Not within normal limits or clinically significant for lab testing; serum chemistries, hematology, urinalysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Below target dose MP-3180
0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
|
MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time.
Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk.
The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
|
ACTIVE_COMPARATOR: 2 times above target dose MP-3180
2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
|
The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time.
Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk.
The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
|
ACTIVE_COMPARATOR: 4 times above target dose MP-3180
4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
|
The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time.
Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk.
The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
|
ACTIVE_COMPARATOR: At target dose MP-3180
1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
|
The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time.
Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk.
The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total plasma clearance of MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
Total plasma clearance (the volume of plasma cleared of the drug over time) was calculated as: Clp = Dose/ AUC∞.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Renal clearance of MP-3180 and iohexol
Time Frame: 60, 120, 240, 360, 600 and 720 minutes post-dose
|
Urine samples were collected pre-dose (time 0) and 5 mL urine samples were collected each time the subject voided. The total volume of urine excreted was recorded until 12 hours post-dose, and analyzed using validated analytical methods. Renal clearance (the volume of plasma cleared of the drug by the kidneys over time) was calculated as: CLr = Ae/ AUClast, where Ae is the cumulative amount of analyte excreted in urine over the sampling interval. |
60, 120, 240, 360, 600 and 720 minutes post-dose
|
Maximum Plasma Concentration (Cmax) for MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Time to Maximum Plasma Concentration (Tmax) for MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The time to maximum plasma concentration (Tmax; measured in hours) was directly determined from the concentration-time data.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
The terminal rate constant for MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The terminal rate constant (λz) was determined by linear regression of the terminal linear phase of the log plasma concentration-time profile.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration for MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The area under the plasma concentration-time curve (ng*hr/mL) was estimated from time 0 to the last measurable concentration using noncompartmental analyses.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Area under the plasma concentration-time curve from time zero to infinity for MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The area under the plasma concentration-time curve (ng*hr/mL) from time 0 to infinity was calculated as: AUC∞ = AUClast + LQC/λz where LQC is the predicted concentration (based on the terminal regression) at the time of the last measurable concentration.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
The elimination half-life of MP-3180 and iohexol
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The elimination half-life (the time required for the concentration of the drug to reach half of its original value) was calculated as t1/2 λz= ln(2)/ λz.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: 1, 3, and 8 hours after dosing, and within 2 weeks after the final study dose
|
An adverse event (AE) was defined as any untoward medical occurrence in a study subject after study drug administration and that did not necessarily have a causal relationship with this treatment.
|
1, 3, and 8 hours after dosing, and within 2 weeks after the final study dose
|
Number of laboratory values that fall outside of pre-specified normal ranges
Time Frame: Pre-dose and within 2 weeks after the final study dose
|
Blood samples were collected and analyzed for hematology and clinical chemistry.
Out of range values were documented.
|
Pre-dose and within 2 weeks after the final study dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between MP-3180 fluorescence intensity and MP-3180 concentration in plasma
Time Frame: Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Blood samples were collected and analyzed using validated analytical methods.
The fluorescence intensity at the time of the blood sampling was compared to plasma concentrations.
|
Pre-dose and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480 and 720 minutes post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORFM-1B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Ain Shams UniversityRecruiting
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
Clinical Trials on Below target dose MP-3180
-
MediBeaconCompletedAcute Kidney Injury | Glomerular Filtration RateUnited States
-
OmicsWay Corp.Oncobox Ltd; Vitamed LLC; N.N. Blokhin National Medical Research Center of Oncology and other collaboratorsActive, not recruitingCancerRussian Federation, United States
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusPoland, United Kingdom, Germany, Romania, Hungary, Denmark, Lithuania
-
LimmaTech Biologics AGGlaxoSmithKlineCompletedKlebsiella Pneumoniae InfectionGermany
-
GlaxoSmithKlineRecruitingSexually Transmitted DiseasesUnited States, Germany, Spain, United Kingdom, France, South Africa, Brazil, Philippines
-
Murdoch Childrens Research InstituteSydney Children's Hospitals Network; Royal Children's Hospital; Monash Health; Royal...Not yet recruitingInfections | Sepsis | BacteremiaAustralia
-
ASST Gaetano Pini-CTOGrisons Foundation for Parkinson's DiseaseCompleted
-
VA Pharmacy Benefits Management Strategic Healthcare...CompletedHypertensionUnited States
-
Albert Einstein College of MedicineFDNY World Trade Center Health ProgramNot yet recruiting
-
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.Completed